These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35717429)

  • 21. Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy.
    Lin CH; Yan JL; Yap WK; Kang CJ; Chang YC; Tsai TY; Chang KP; Liao CT; Hsu CL; Chou WC; Wang HM; Huang PW; Fan KH; Huang BS; Tung-Chieh Chang J; Tu SJ; Lin CY
    Radiother Oncol; 2023 Dec; 189():109938. PubMed ID: 37806562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the radiomics-machine-learning model based on non-contrast enhanced CT for the simplified risk categorization of thymic epithelial tumors: A large cohort retrospective study.
    Feng XL; Wang SZ; Chen HH; Huang YX; Xin YK; Zhang T; Cheng DL; Mao L; Li XL; Liu CX; Hu YC; Wang W; Cui GB; Nan HY
    Lung Cancer; 2022 Apr; 166():150-160. PubMed ID: 35287067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
    Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
    Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.
    Ter-Minassian M; Zhang S; Brooks NV; Brais LK; Chan JA; Christiani DC; Lin X; Gabriel S; Dinet J; Kulke MH
    Oncologist; 2017 Feb; 22(2):165-172. PubMed ID: 28179574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reproducibility and non-redundancy of radiomic features extracted from arterial phase CT scans in hepatocellular carcinoma patients: impact of tumor segmentation variability.
    Qiu Q; Duan J; Duan Z; Meng X; Ma C; Zhu J; Lu J; Liu T; Yin Y
    Quant Imaging Med Surg; 2019 Mar; 9(3):453-464. PubMed ID: 31032192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of texture analysis for grading pancreatic neuroendocrine tumors on contrast-enhanced computed tomography and apparent diffusion coefficient maps.
    Ohki K; Igarashi T; Ashida H; Takenaga S; Shiraishi M; Nozawa Y; Ojiri H
    Jpn J Radiol; 2021 Jan; 39(1):66-75. PubMed ID: 32885378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrimination of Liver Metastases of Digestive System Neuroendocrine Tumors From Neuroendocrine Carcinoma by Computed Tomography-Based Radiomics Analysis.
    Gu XL; Cui Y; Zhu HT; Li XT; Pei X; He XX; Yang L; Lu M; Li ZW; Sun YS
    J Comput Assist Tomogr; 2023 May-Jun 01; 47(3):361-368. PubMed ID: 37184997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-based radiomics to distinguish progressive from stable neuroendocrine liver metastases treated with somatostatin analogues: an explorative study.
    Staal FC; Taghavi M; Hong EK; Tissier R; van Treijen M; Heeres BC; van der Zee D; Tesselaar ME; Beets-Tan RG; Maas M
    Acta Radiol; 2023 Mar; 64(3):1062-1070. PubMed ID: 35702011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms.
    Loi S; Mori M; Benedetti G; Partelli S; Broggi S; Cattaneo GM; Palumbo D; Muffatti F; Falconi M; De Cobelli F; Fiorino C
    Phys Med; 2020 Aug; 76():125-133. PubMed ID: 32673824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computed Tomography-Based Radiomics Model to Predict Central Cervical Lymph Node Metastases in Papillary Thyroid Carcinoma: A Multicenter Study.
    Li J; Wu X; Mao N; Zheng G; Zhang H; Mou Y; Jia C; Mi J; Song X
    Front Endocrinol (Lausanne); 2021; 12():741698. PubMed ID: 34745008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiomic analysis to predict local response in locally advanced pancreatic cancer treated with stereotactic body radiation therapy.
    Gregucci F; Fiorentino A; Mazzola R; Ricchetti F; Bonaparte I; Surgo A; Figlia V; Carbonara R; Caliandro M; Ciliberti MP; Ruggieri R; Alongi F
    Radiol Med; 2022 Jan; 127(1):100-107. PubMed ID: 34724139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center.
    Kiesewetter B; Melhorn P; Macheiner S; Wolff L; Kretschmer-Chott E; Haug A; Mazal P; Raderer M
    J Neuroendocrinol; 2023 Aug; 35(8):e13319. PubMed ID: 37485760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CT-Radiomic Approach to Predict G1/2 Nonfunctional Pancreatic Neuroendocrine Tumor.
    Zhao Z; Bian Y; Jiang H; Fang X; Li J; Cao K; Ma C; Wang L; Zheng J; Yue X; Zhang H; Wang X; Madabhushi A; Xu J; Jin G; Lu J
    Acad Radiol; 2020 Dec; 27(12):e272-e281. PubMed ID: 32037260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma.
    Kulanthaivelu R; Kohan A; Hinzpeter R; Liu ZA; Hope A; Huang SH; Waldron J; O'Sullivan B; Ortega C; Metser U; Veit-Haibach P
    Front Oncol; 2022; 12():952763. PubMed ID: 36353565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin and everolimus in neuroendocrine tumours: A synergic effect?
    Hue-Fontaine L; Lemelin A; Forestier J; Raverot G; Milot L; Robinson P; Borson-Chazot F; Lombard-Bohas C; Walter T
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):954-960. PubMed ID: 32146090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
    Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
    Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors.
    Benedetti G; Mori M; Panzeri MM; Barbera M; Palumbo D; Sini C; Muffatti F; Andreasi V; Steidler S; Doglioni C; Partelli S; Manzoni M; Falconi M; Fiorino C; De Cobelli F
    Radiol Med; 2021 Jun; 126(6):745-760. PubMed ID: 33523367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.